This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0269881107082901v1 22/3/244    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mir, A. Articles by Aitchison, K. J Search for Related Content PubMed PubMed Citation Articles by Mir, A. Articles by Aitchison, K. J Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Change in sexual dysfunction with aripiprazole: a switching or add–on study

¹ Team (Croydon Early Intervention in Psychosis Service), Westways Resource Centre, Croydon, UK.
² COAST Team (Croydon Early Intervention in Psychosis Service), Westways Resource Centre, Croydon, UK and MRC Social, Genetic and Developmental Psychiatry Research Centre and Clinical Neuropharmacology, Division of Psychological Medicine and Psychiatry, London, UK..
³ MRC Social, Genetic and Developmental Psychiatry Research Centre and Clinical Neuropharmacology, Division of Psychological Medicine and Psychiatry, London, UK.
⁴ COAST Team (Croydon Early Intervention in Psychosis Service), Westways Resource Centre, Croydon, UK.
⁵ Perinatal Psychiatry Section, Division of Psychological Medicine and Psychiatry, London, UK.
⁶ MRC Social, Genetic and Developmental Psychiatry Research Centre and Clinical Neuropharmacology, Division of Psychological Medicine and Psychiatry, London, UK and COAST Team (Croydon Early Intervention in Psychosis Service), Westways Resource Centre, Croydon, UK

^* To whom correspondence should be addressed.

	Abstract

Sexual dysfunction and raised prolactin are common adverse effects of many anti–psychotics. Aripiprazole is an atypical anti–psychotic associated with a reduction in prolactin level in anti–psychotic–induced hyperprolactinemia. Our hypothesis was that switching from another anti–psychotic to aripiprazole would be associated with a reduction in sexual dysfunction. An open label switch to aripiprazole was offered to 27 subjects with inadequate therapeutic response or intolerance to another anti–psychotic, who were followed up for 26 weeks. Serial clinical ratings included the Anti–psychotic Non–Neurological Side–Effects Rating Scale (ANNSERS), and the Sexual Functioning Questionnaire. Our primary analysis point was week 12. In both sexes, there was a significant reduction in prolactin by week 12 (P 5 0.003), accompanied by a significant improvement in libido (P 5 0.028). In males, both erectile and ejaculatory difficulties were also significantly reduced (P 5 0.04 and P 5 0.017, respectively). In females, menstrual dysfunction was also significantly reduced at week 12 (P 5 0.04). By week 26, the changes in all of the above remained significant, and were accompanied by a significant increase in satisfaction in overall sexual functioning (P 5 0.007), despite the fact that 54.5% of subjects at were also taking their original antipsychotic. There was also a significant decrease in the total ANNSERS score (P , 0.001) and a significant improvement in all other measures of psychopathology (PANSS, CGI–S/I, GAF–S/D, and QoL). We conclude that switching to aripiprazole or the addition of aripiprazole to another antipsychotic regime is associated with a reduction in sexual dysfunction.

Key Words: aripiprazole, anti–spsychotic agent, prolactin, sexual dysfunction, dopamine agonist

First published on February 28, 2008, doi:10.1177/0269881107082901

Journal of Psychopharmacology 2008;22:244.

A more recent version of this article appeared on May 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?